Netherlands-based Bedrocan International has been recognised as the world’s first producer of medicinal cannabis to be compliant with the European Medicines Agency’s good manufacturing practice (GMP) standards.

The latest news follows an inspection carried out by the Dutch Health Care Inspectorate.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Following the announcement, Bedrocan’s production facilities located in Canada and the Czech Republic are expected to become fully compliant next year.

The company stated that GMP is the highest standard to be met by a medicine manufacturer in its production process.

Bedrocan International chairman Tjalling Erkelens said: “This is a significant recognition.

See Also:

“We have always aimed to meet the highest pharmaceutical standards. Now our way of working is officially recognised by the authorities.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"A key factor in our ability to provide a pharmaceutical-grade solution is Bedrocan’s standardised product and uncompromising quality."

The company has produced standardised medicinal cannabis as an active pharmaceutical ingredient (API) since 2003.

It produces cannabis flos (the whole, dried flower) with a constant composition of cannabinoids and terpenes.

Bedrocan’s medicinal cannabis supplies patients and researchers in countries such as the Netherlands, Australia, Germany, Finland, Israel, Italy, Macedonia and Poland.

Israel’s Syqe Medical incorporates Bedrocan’s medicinal cannabis in its metered-dose inhaler.

Syqe Medical CEO and founder Perry Davidson said: “Syqe Medical has developed the world’s first inhaler that delivers medicinal cannabis with the level of precision of traditional medicines.

“A key factor in our ability to provide a pharmaceutical-grade solution is Bedrocan’s standardised product and uncompromising quality.”